BIOA
Get informed when a big investor buys or sells
+ FollowOvervalued by 29.2% based on the discounted cash flow analysis.
| Market cap | $44.12 Billion |
|---|---|
| Enterprise Value | $43.94 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.24 |
| Beta | 0.93 |
| Outstanding Shares | 44,838,893 |
| P/E Ratio | -4.05 |
|---|---|
| PEG | -0.71 |
| Price to Sales | - |
| Price to Book Ratio | 1.58 |
| Enterprise Value to Revenue | 3364.97 |
| Enterprise Value to EBIT | -584.59 |
| Enterprise Value to Net Income | -623 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1210▼ 670.48% |
|---|---|
| Total Calls | 888,610▲ 5632.97% |
| Total Puts | 107,500▲ 1.61% |
Holdings and activity of institutional investors.
| Ownership % | 89.50%▲ 8.78% |
|---|---|
| Total Invested | $931.83M▲ 55.50% |
| Investors Holding | 164▲ 16.00% |
No data
This particular fund is offered as a component within the ProShares Trust framework. Its central objective is to generate steady income, while concurrently prioritizing accessible funds and the safeguarding of investors' principal. A key...